APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-11

Price

$134.69

+0.03%

This is the 2026-08-11 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score15.0Top Tier

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 7

Volume0.9xvs 20d avg

Analysis

Apogee Therapeutics is trading as a pure merger arbitrage play following AbbVie's definitive agreement to acquire the company for $135.11 per share in cash. The technical signals like SURGE and QUIET_STORM, alongside the ultra-low 1.9% annualized volatility, are structural artifacts of the stock pinning near the deal price rather than organic momentum. Furthermore, the broader RISK_ON macro regime and exceptionally tight credit spreads (0.78%) give arbitrageurs supreme confidence, keeping the deal spread incredibly narrow due to zero financing stress in the system.

Fired Signals

SURGEALPHA MALEQUIET STORMGOLDEN CROSSPERFECT STACKSELLER FATIGUEINSIDE OUT

Key Takeaways

Apogee is a capped merger arbitrage play driven by AbbVie's $135.11 per share all-cash acquisition.
Recent technical signals and ultra-low volatility reflect institutional spread-collecting rather than organic price discovery.
With shareholders approving the merger on August 11, the primary remaining risk is an unexpected regulatory hurdle before closing.

← Back to 2026-08-11 View Full APGE History →Yahoo Finance &nearr;